✦ LIBER ✦

P-205 Lack of b-tubulin gene mutations in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p) at time of tumor progression

✍ Scribed by Queralt, Cristina; Roig, Barbara; Sarries, Carme; Botia, Monica; Nun˜ez, Laura; Ramirez, JoséLuis; Mendez, Pedro; Sánchez, JoséMiguel; Taron, Miquel; Rosell, Rafael

Book ID: 118571906
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 233 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92174-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-220 Polymorphisms in DNA repair genes

P-220 Polymorphisms in DNA repair genes and survival in cisplatin (cis)/docetaxel (doc)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p): a Spanish Lung Cancer Group phase II trial

✍ Isla, Dolores; Queralt, Cristina; Alonso, Guillermo; Domine, Manuel; Barcelo, Ra 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 174 KB

6534 POSTER Elevated levels of thioredox

6534 POSTER Elevated levels of thioredoxin (Trx) in serum correlate with poor outcome in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small-cell lung cancer (NSCLC) patients (pts)

✍ Molina, M.A.; Camps, C.; DelasPeñas, R.; Alonso, G.; Lopez-Vivanco, G.; Provenci 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

O-089 ERCC1 mRNA-based randomized phase

O-089 ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p)

✍ Cobo, M.; Isla, D.; Sánchez, J.; Massuti, B.; Montes, A.; Paz-Ares, L.; Múñoz, M 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 131 KB

P-224 XPD polymorphisms in cisplatin (ci

P-224 XPD polymorphisms in cisplatin (cis)/vinorelbine (vrb)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p): genetic analysis of a Spanish Lung Cancer Group phase II trial

✍ Vin˜olas, Nuria; Roig, Barbara; Reguart, Noemi; Provencio, Mariano; Cardenal, Fe 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 178 KB

P-225 XPD and RRM1 gene polymorphisms pr

P-225 XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/cisplatin (cis)/docetaxel (doc) outcome in stage III non-small-cell lung cancer (NSCLC): a genetic analysis of the Spanish Lung Cancer Group phase II trial 9901

✍ Sarries, Carme; Garrido, Pilar; Nun˜ez, Laura; Roig, Barbara; Ramirez, Jose Luis 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 178 KB

O-033 Docetaxel (DOC), cisplatin (CIS) a

O-033 Docetaxel (DOC), cisplatin (CIS) and gemcitabine (GEM) asneoadjuvant treatment in stage IIIAN2 and T4N0-1 non-small cell lung cancer (NSCLC) patients (P). final results of SLCG phase II trial 9901

✍ Garrido, P.; Rosell, R.; Torres, A.; González Larriba, J.; Provencio, M.; Isla, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 150 KB